• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC TO-T/A filed by Turnstone Biologics Corp.

    8/11/25 9:15:03 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TSBX alert in real time by email
    SC TO-T/A 1 d60598dsctota.htm SC TO-T/A SC TO-T/A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE TO

    TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)

     

     

    TURNSTONE BIOLOGICS CORP.

    (Name of Subject Company (Issuer))

    XOMA ROYALTY CORPORATION

    (Name of Filing Persons (Offeror))

    Common Stock, Par Value $0.001 Per Share

    (Title of Class of Securities)

    98419J206

    (CUSIP Number of Class of Securities)

    Owen Hughes

    XOMA Royalty Corporation

    2200 Powell Street, Suite 310

    Emeryville, California 94608

    Tel. (510) 204-7200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

    Copies to:

    Ryan A. Murr

    Branden C. Berns

    Melanie E. Neary

    Gibson, Dunn & Crutcher LLP

    One Embarcadero Center, Suite 2600

    San Francisco, CA 94111

     

     

     

    ☐

    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

    Check the appropriate boxes below to designate any transactions to which the statement relates:

     

    ☒

    third-party tender offer subject to Rule 14d-1.

     

    ☐

    issuer tender offer subject to Rule 13e-4.

     

    ☐

    going-private transaction subject to Rule 13e-3.

     

    ☐

    amendment to Schedule 13D under Rule 13d-2.

    Check the following box if the filing is a final amendment reporting the results of the tender offer. ☒

    If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

     

    ☐

    Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

     

    ☐

    Rule 13d-1(d) (Cross-Border Third-Party Tender Offer)

     

     
     


    This Amendment No. 2 (this “Amendment”) amends and supplements the Tender Offer Statement on Schedule TO originally filed under cover of Schedule TO on July 11, 2025, as amended by Amendment No. 1 filed with the SEC on July 24, 2025 (together with any subsequent amendments and supplements thereto, the “Schedule TO”), by XOMA Royalty Corporation, a Nevada corporation (“Purchaser”). This Amendment relates to the offer (the “Offer”) to purchase all of the outstanding shares of common stock, par value $0.001 per share (“Shares”), of Turnstone Biologics Corp., a Delaware corporation (“Turnstone”), for a price per Share of (i) $0.34 (the “Cash Amount”), payable subject to any applicable tax withholding and without interest, and (ii) one non-transferable contractual contingent value right (“CVR”) for each Share, which shall represent the right to receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the CVR Agreement (as described below), subject to any applicable tax withholding and without interest (such amount, the “CVR Amount,” and together with the Cash Amount, the “Offer Price”), all upon the terms and subject to the conditions described in the Amended and Restated Offer to Purchase, dated July 23, 2025 (together with any amendments or supplements thereto, the “Offer to Purchase”) and in the related Letter of Transmittal, copies of which are attached to the Schedule TO as exhibits (a)(1)(E) and (a)(1)(B), respectively. The Offer is being made pursuant to the Agreement and Plan of Merger, dated as of June 26, 2025 (together with any amendments or supplements thereto, the “Merger Agreement”), among Turnstone, Purchaser and XRA 3 Corp., a Delaware corporation and a wholly owned subsidiary of Purchaser (“Merger Sub”), a copy of which is filed as Exhibit (d)(1) to the Schedule TO and incorporated herein by reference with respect to Items 4 through 11 of this Amendment.

    Except as otherwise set forth in this Amendment, all terms of the Offer and all other disclosures set forth in the Schedule TO and the Exhibits thereto remain unchanged and are hereby expressly incorporated into this Amendment by reference. This Amendment should be read together with the Schedule TO. Capitalized terms used and not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Schedule TO and the Offer to Purchase.

    ITEMS 1 THROUGH 9 AND 11

    Items 1 through 9 and 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:

    “Closing of the Merger

    The Offer expired as scheduled, one minute past 11:59 p.m. Eastern Time on August 7, 2025 (the “Expiration Date”) and was not extended. The Depositary and Paying Agent has advised Purchaser that, as of the Expiration Date, a total of 17,192,002 Shares were validly tendered into, and not validly withdrawn from, the Offer, representing approximately 74% of Shares that were issued and outstanding as of the Expiration Date. All conditions to the Offer, including the Minimum Tender Condition, having been satisfied or waived, Purchaser irrevocably accepted for payment, and made payment for all Shares validly tendered and not validly withdrawn in the Offer.

    On August 11, 2025, Purchaser completed the acquisition of Turnstone pursuant to the terms of the Merger Agreement through the merger of Merger Sub with and into Turnstone in accordance with Section 251(h) of the DGCL, with Turnstone continuing as the surviving corporation in the Merger and thereby becoming a wholly owned subsidiary of Purchaser. At the Effective Time, each issued and outstanding Share not tendered into the Offer (other than any Excluded Shares or Dissenting Shares) was automatically converted into the right to receive the Offer Price.

    The Shares ceased to trade on Nasdaq prior to the commencement of trading on August 11, 2025, and Turnstone has requested that Nasdaq file a Notification of Removal from Listing and/or Registration under Section 12(b) of the Exchange Act on Form 25 to delist and deregister the Shares. Purchaser and Turnstone intend to file a certification and notice of termination of registration on Form 15 with the SEC requesting the termination of registration of the Shares under Section 12(g) of the Exchange Act and the suspension of reporting obligations under Section 13 and 15(d) of the Exchange Act with respect to the Shares and take steps to cause the termination of the registration of the Shares under the Exchange Act and suspend all of Turnstone’s reporting obligations under the Exchange Act as promptly as practicable.”

     

    2


    ITEM 12. EXHIBITS.

    Item 12 of the Schedule TO is hereby amended and supplemented by adding the following Exhibit to the list of Exhibits:

     

    Index No.    
    (a)(5)(B)*   Press Release of Purchaser issued on August 11, 2025.

     

    *

    Filed herewith.

     

    3


    SIGNATURE

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: August 11, 2025

     

    XOMA Royalty Corporation
    By:  

    /s/ Owen Hughes

      Name:   Owen Hughes
      Title:   Chief Executive Officer

     

    4

    Get the next $TSBX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TSBX

    DatePrice TargetRatingAnalyst
    2/5/2025$3.75 → $0.40Overweight → Neutral
    Piper Sandler
    11/15/2024Neutral → Underperform
    BofA Securities
    10/14/2024Buy → Neutral
    BofA Securities
    8/16/2023Market Perform
    SVB Securities
    8/15/2023$20.00Overweight
    Piper Sandler
    8/15/2023$18.00Buy
    BofA Securities
    More analyst ratings

    $TSBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Turnstone Biologics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Turnstone Biologics from Overweight to Neutral and set a new price target of $0.40 from $3.75 previously

    2/5/25 8:04:09 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Turnstone Biologics downgraded by BofA Securities

    BofA Securities downgraded Turnstone Biologics from Neutral to Underperform

    11/15/24 8:23:44 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Turnstone Biologics downgraded by BofA Securities

    BofA Securities downgraded Turnstone Biologics from Buy to Neutral

    10/14/24 7:44:47 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Orbimed Advisors Llc

    4 - Turnstone Biologics Corp. (0001764974) (Issuer)

    8/12/25 5:22:13 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Large owner Versant Ventures V, Llc

    4 - Turnstone Biologics Corp. (0001764974) (Issuer)

    8/12/25 4:34:57 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Jerel Davis

    4 - Turnstone Biologics Corp. (0001764974) (Issuer)

    8/8/25 4:06:58 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

    - Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Turnstone Biologics Corp. (NASDAQ:TSBX) common stock for a price per share of $0.34 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Pr

    8/11/25 9:00:00 AM ET
    $TSBX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

    EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best

    6/27/25 7:30:00 AM ET
    $TSBX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

    SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to explore a range of potentia

    5/8/25 6:00:49 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Turnstone Biologics Corp.

    SCHEDULE 13D/A - Turnstone Biologics Corp. (0001764974) (Subject)

    8/12/25 4:44:49 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by Turnstone Biologics Corp.

    S-8 POS - Turnstone Biologics Corp. (0001764974) (Filer)

    8/11/25 4:50:28 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by Turnstone Biologics Corp.

    S-8 POS - Turnstone Biologics Corp. (0001764974) (Filer)

    8/11/25 4:48:53 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

    SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

    5/31/24 4:23:52 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

    SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

    4/29/24 8:22:22 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Turnstone Biologics Corp.

    SC 13G - Turnstone Biologics Corp. (0001764974) (Subject)

    3/18/24 9:13:28 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Leadership Updates

    Live Leadership Updates

    View All

    Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

    SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity

    5/13/24 5:01:26 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Turnstone Biologics Appoints William Waddill to its Board of Directors

    SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

    4/16/24 9:00:00 AM ET
    $ANNX
    $ARWR
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

    Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported

    3/21/24 5:06:41 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Financials

    Live finance-specific insights

    View All

    Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

    EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best

    6/27/25 7:30:00 AM ET
    $TSBX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

    SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t

    3/28/25 9:03:57 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care